INmune Bio Inc. - Common stock (INMB): Price and Financial Metrics
GET POWR RATINGS... FREE!
INMB POWR Grades
- Sentiment is the dimension where INMB ranks best; there it ranks ahead of 81.02% of US stocks.
- The strongest trend for INMB is in Value, which has been heading up over the past 178 days.
- INMB's current lowest rank is in the Momentum metric (where it is better than 13.65% of US stocks).
INMB Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for INMB is 0.01 -- better than merely 8.49% of US stocks.
- INMB's price/sales ratio is 315.73; that's higher than the P/S ratio of 98.72% of US stocks.
- As for revenue growth, note that INMB's revenue has grown 106.63% over the past 12 months; that beats the revenue growth of 93.38% of US companies in our set.
- Stocks that are quantitatively similar to INMB, based on their financial statements, market capitalization, and price volatility, are ORMP, BCYC, SYNA, LYEL, and TERN.
- INMB's SEC filings can be seen here. And to visit INMUNE BIO INC's official web site, go to www.inmunebio.com.
INMB Valuation Summary
- INMB's price/earnings ratio is -4.3; this is 119.03% lower than that of the median Healthcare stock.
- INMB's price/earnings ratio has moved up 89.2 over the prior 50 months.
Below are key valuation metrics over time for INMB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| INMB | 2023-03-17 | 315.8 | 2.0 | -4.3 | -3.0 |
| INMB | 2023-03-16 | 337.7 | 2.1 | -4.6 | -3.3 |
| INMB | 2023-03-15 | 326.7 | 2.0 | -4.5 | -3.1 |
| INMB | 2023-03-14 | 333.4 | 2.1 | -4.6 | -3.2 |
| INMB | 2023-03-13 | 342.5 | 2.1 | -4.7 | -3.3 |
| INMB | 2023-03-10 | 331.6 | 2.1 | -4.5 | -3.2 |
INMB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- INMB has a Quality Grade of D, ranking ahead of 11.03% of graded US stocks.
- INMB's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows INMB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | 1 | -3.952 |
| 2021-03-31 | 0 | 1 | -15.163 |
| 2020-12-31 | 0 | 1 | -22.264 |
| 2020-09-30 | 0 | NA | -21.947 |
| 2020-06-30 | 0 | NA | -15.048 |
| 2020-03-31 | 0 | NA | -9.777 |
INMB Price Target
For more insight on analysts targets of INMB, see our INMB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.75 | Average Broker Recommendation | 1.38 (Strong Buy) |
INMB Stock Price Chart Interactive Chart >
INMB Price/Volume Stats
| Current price | $6.20 | 52-week high | $10.75 |
| Prev. close | $6.58 | 52-week low | $4.63 |
| Day low | $6.05 | Volume | 92,000 |
| Day high | $6.84 | Avg. volume | 55,930 |
| 50-day MA | $8.38 | Dividend yield | N/A |
| 200-day MA | $8.00 | Market Cap | 111.27M |
INmune Bio Inc. - Common stock (INMB) Company Bio
INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.
Latest INMB News From Around the Web
Below are the latest news stories about INMUNE BIO INC that investors may wish to consider to help them evaluate INMB as an investment opportunity.
INmune Bio, Inc.'s (NASDAQ:INMB) top owners are retail investors with 55% stake, while 25% is held by insidersKey Insights Significant control over INmune Bio by retail investors implies that the general public has more power to... |
INmune Bio, Inc. (NASDAQ:INMB) Q4 2022 Earnings Call TranscriptINmune Bio, Inc. (NASDAQ:INMB) Q4 2022 Earnings Call Transcript March 3, 2023 Operator: Greetings, and welcome to the INmune Bio Fourth Quarter and Full Year 2022 Earnings Call. This conference will be recorded. A brief question-and-answer session will follow the formal presentation. It is now my pleasure to introduce Mr. David Moss, CFO of INmune […] |
Q4 2022 INmune Bio Inc Earnings CallQ4 2022 INmune Bio Inc Earnings Call |
INmune Bio, Inc. Announces 2022 Results and Provides Business UpdateCompany to Host Conference Call Today, March 2, at 4:30pm ETBOCA RATON, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the year ended December 31, 2022 and provides a business update. Q4 2022 and 2022 Corporate Highlights: DN-TNF Platform Highlights (XPro™ and INB03™): Consolidat |
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Feb. 21, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, March 2, 2023 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2022 and to provide a corp |
INMB Price Returns
| 1-mo | -36.99% |
| 3-mo | -11.55% |
| 6-mo | -19.48% |
| 1-year | -21.72% |
| 3-year | 122.22% |
| 5-year | N/A |
| YTD | -2.21% |
| 2022 | -37.84% |
| 2021 | -40.77% |
| 2020 | 196.90% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...